6,840 reports of this reaction
2.2% of all RANITIDINE reports
#10 most reported adverse reaction
PANCREATIC CARCINOMA is the #10 most commonly reported adverse reaction for RANITIDINE, manufactured by Ajanta Pharma USA Inc.. There are 6,840 FDA adverse event reports linking RANITIDINE to PANCREATIC CARCINOMA. This represents approximately 2.2% of all 308,223 adverse event reports for this drug.
RANITIDINE has an overall safety score of 95 out of 100. Patients taking RANITIDINE who experience pancreatic carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PANCREATIC CARCINOMA is a less commonly reported adverse event for RANITIDINE, but still significant enough to appear in the safety profile.
In addition to pancreatic carcinoma, the following adverse reactions have been reported for RANITIDINE:
The following drugs have also been linked to pancreatic carcinoma in FDA adverse event reports:
PANCREATIC CARCINOMA has been reported as an adverse event in 6,840 FDA reports for RANITIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PANCREATIC CARCINOMA accounts for approximately 2.2% of all adverse event reports for RANITIDINE, making it a notable side effect.
If you experience pancreatic carcinoma while taking RANITIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.